Yupelri FDA Approval History
FDA Approved: Yes (First approved November 9, 2018)
Brand name: Yupelri
Generic name: revefenacin
Dosage form: Inhalation Solution
Company: Theravance, Inc.
Treatment for: COPD
Yupelri (revefenacin) is a long-acting muscarinic antagonist (LAMA) for the treatment of chronic obstructive pulmonary disease (COPD).
Development timeline for Yupelri
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.